<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04534127</url>
  </required_header>
  <id_info>
    <org_study_id>CTP-CMN-02_</org_study_id>
    <nct_id>NCT04534127</nct_id>
  </id_info>
  <brief_title>Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia</brief_title>
  <official_title>A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpha Tau Medical LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpha Tau Medical LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A unique approach for cancer treatment employing intratumoral diffusing alpha radiation&#xD;
      emitter device for superficial cutaneous, mucosal or soft tissue neoplasia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, open label, single arm, controlled study, assessing the safety&#xD;
      and efficacy of diffusing alpha emitters radiation therapy (DaRT) delivered through&#xD;
      radioactive seeds inserted into the tumor.&#xD;
&#xD;
      This approach combines the advantages of local intratumoral irradiation of the tumor, as used&#xD;
      in conventional brachytherapy, with the power of the alpha radiation emitting atoms, that&#xD;
      will be introduced in quantities considerably lower than radiation therapy already used in&#xD;
      patients.&#xD;
&#xD;
      Superficial lesions with histopathological confirmation of malignancy will be treated using&#xD;
      DaRT seeds.&#xD;
&#xD;
      Reduction in tumor size 70 days after DaRT insertion will be assessed. Safety will be&#xD;
      assessed by the incidence, severity and frequency of all Adverse Events (AE).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response to DaRT</measure>
    <time_frame>9-11 weeks post DaRT insertion</time_frame>
    <description>Assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>The incidence, frequency, severity and causality of acute adverse events related to the DaRT treatment according to Common Terminology and Criteria for adverse events (CTCAE) version 5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in tumor volume</measure>
    <time_frame>9-11 weeks post DaRT insertion</time_frame>
    <description>Based on imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DaRT seeds placement</measure>
    <time_frame>1 Day of procedure</time_frame>
    <description>Assessment by localization of the DaRT seeds in the tumor using CT imaging on the day of DaRT insertion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Day 15, Day 30, Day 70, Day 180 post DaRT insertion</time_frame>
    <description>Assessment of patient reported health-related Quality of Life outcome after DaRT, using QoL questionnaire Skindex-16 questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Day 30, Day 70, Day 180 post DaRT insertion</time_frame>
    <description>Assessment of patient reported health-related Quality of Life outcome after DaRT, using QoL questionnaire Skin Cancer Index (SCI) questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>24 months post DaRT insertion</time_frame>
    <description>Time elapsed from response to disease progression</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>All Adverse Events (AE) related and unrelated to the study treatment</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Skin Cancer</condition>
  <condition>Mucosal Neoplasm of Oral Cavity</condition>
  <condition>Soft Tissue Neoplasm</condition>
  <arm_group>
    <arm_group_label>DaRT Seeds</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)</intervention_name>
    <description>An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.</description>
    <arm_group_label>DaRT Seeds</arm_group_label>
    <other_name>DaRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with histopathological confirmation of primary or secondary malignant&#xD;
             cutaneous neoplastic lesions, or oral cavity mucosal tumors, or superficial soft&#xD;
             tissue sarcoma. Confirmation obtained within 6 months of planned treatment.&#xD;
&#xD;
          -  Subjects with a tumor size ≤ 7 centimeters in the longest diameter.&#xD;
&#xD;
          -  Targetable lesion must be technically amenable for complete coverage (including&#xD;
             margins) by the DaRT seeds&#xD;
&#xD;
          -  Brachytherapy indication validated by a multidisciplinary team&#xD;
&#xD;
          -  Patients who have either failed first-line treatment, or are medically unfit for&#xD;
             standard of care (surgery, external-beam radiation therapy or chemotherapy), or refuse&#xD;
             standard of care.&#xD;
&#xD;
          -  Measurable disease according to RECIST v1.1.&#xD;
&#xD;
          -  Subjects over 18 years old.&#xD;
&#xD;
          -  Subjects' ECOG Performance Status Scale is &lt; 2.&#xD;
&#xD;
          -  Subjects' life expectancy is more than 6 months.&#xD;
&#xD;
          -  Platelet count ≥100,000/mm3.&#xD;
&#xD;
          -  WBC ≥ 3500/μl, granulocyte ≥ 1500/μl&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 X ULN&#xD;
&#xD;
          -  International normalized ratio of prothrombin time ≤1.8.&#xD;
&#xD;
          -  Creatinine ≤1.9 mg/dL. Women of childbearing potential (WOCBP) will have evidence of&#xD;
             negative pregnancy test and are required to use an acceptable contraceptive method to&#xD;
             prevent pregnancy for 3 months after brachytherapy.&#xD;
&#xD;
          -  Subjects are willing to sign an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a tumor of Keratoacanthoma histology.&#xD;
&#xD;
          -  Known hypersensitivity to any of the components of the treatment.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart&#xD;
             Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy,&#xD;
             uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial&#xD;
             infarction in the last 12 months.&#xD;
&#xD;
          -  Any medical or psychiatric illness which in the opinion of the investigator would&#xD;
             compromise the patient's ability to tolerate this treatment or interfere with the&#xD;
             study endpoints.&#xD;
&#xD;
          -  Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief&#xD;
             use of systemic corticosteroids&#xD;
&#xD;
          -  Patient requires treatment which may conflict with the endpoints of this study&#xD;
             including evaluation of response or toxicity of DaRT&#xD;
&#xD;
          -  Volunteers participating in another interventional study in the past 30 days which&#xD;
             might conflict with the endpoints of this study or the evaluation of response or&#xD;
             toxicity of DaRT.&#xD;
&#xD;
          -  Patients must agree to use adequate contraception (vasectomy or barrier method of&#xD;
             birth control) prior to study entry, for the duration of study participation and for 3&#xD;
             months after discontinuing therapy.&#xD;
&#xD;
          -  High probability of protocol non-compliance (in opinion of investigator).&#xD;
&#xD;
          -  Subjects not willing to sign an informed consent.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aron Popovtzer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sharett institute, Hadassah University Hospital - Ein-Kerem</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vladislav Rud</last_name>
    <phone>+972-2-3737-212</phone>
    <email>vladir@alphatau.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naama Barel</last_name>
    <phone>+972-2-3737-210</phone>
    <email>naamab@alphatau.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sharett institute, Hadassah Medical Center - Ein-Kerem</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aron Popovtzer, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Squamous Cell Carcinoma</keyword>
  <keyword>SCC</keyword>
  <keyword>Skin Cancer</keyword>
  <keyword>Skin metastasis</keyword>
  <keyword>HNSCC</keyword>
  <keyword>Carcinoma, Squamous</keyword>
  <keyword>CMN</keyword>
  <keyword>Basal cell carcinoma</keyword>
  <keyword>Superficial sarcoma</keyword>
  <keyword>Kaposi sarcoma</keyword>
  <keyword>Alpha radiation</keyword>
  <keyword>Cutaneous lesion</keyword>
  <keyword>Tongue cancer</keyword>
  <keyword>Lip cancer</keyword>
  <keyword>Brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Soft Tissue Neoplasms</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

